Parenteral nutrition (PN) represents one of the most notable achievements of modern medicine, serving as a therapeutic modality for all age groups across the healthcare continuum. PN offers a life-sustaining option when intestinal failure prevents adequate oral or enteral nutrition. However, providing nutrients by vein is an expensive form of nutrition support, and serious adverse events can occur. In an effort to provide clinical guidance regarding PN therapy, the Board of Directors of the American Society for Parenteral and Enteral Nutrition (ASPEN) convened a task force to develop consensus recommendations regarding appropriate PN use. The recommendations contained in this document aim to delineate appropriate PN use and promote clinical benefits while minimizing the risks associated with the therapy. These consensus recommendations build on previous ASPEN clinical guidelines and consensus recommendations for PN safety. They are intended to guide evidence-based decisions regarding appropriate PN use for organizations and individual professionals, including physicians, nurses, dietitians, pharmacists, and other clinicians involved in providing PN. They not only support decisions related to initiating and managing PN but also serve as a guide for developing quality monitoring tools for PN and for identifying areas for further research. Finally, the recommendations contained within the document are also designed to inform decisions made by additional stakeholders, such as policy makers and third-party payers, by providing current perspectives regarding the use of PN in a variety of healthcare settings. (JPEN J Parenter Enteral Nutr. 2017;41:324-377) The etiology-based nutrition diagnoses in adults in clinical practice settings are as follows: Starvation-related malnutrition: Chronic starvation without inflammation (eg, anorexia nervosa). Chronic disease-related malnutrition: Inflammation is chronicand of mild to moderate degree (eg, organ failure, pancreatic cancer, rheumatoid arthritis, sarcopenic obesity). Acute disease or injury-related malnutrition:Inflammation is acute and of severe degree (eg, major infection burns, trauma, closed head injury). 2,3Malnutrition, pediatric: An imbalance between nutrient requirement and intake, resulting in cumulative deficits of energy, protein, or micronutrients that may negatively affect growth, development, and other relevant outcomes. It is recommended that growth charts based on a standard deviation z score system be used to track and assess nutrition status in children. 4,5Nutritionally-at-risk: Consider the individual nutritionally-atrisk if any of the following is present. Nutritionally-At-Risk Adult Summary of RecommendationsThese consensus recommendations are designed to identify best practices, guide day-to-day clinical decisions, reduce variations in practice, and enhance patient safety. They are not intended to supersede the judgment of the healthcare professional based on the circumstances of the individual patient.

No abstract

To estimate associations of exclusive human milk (EHM) feedings with growth and neurodevelopment through 18 months corrected age (CA) in extremely low birth weight (ELBW) infants. ELBW infants admitted from July 2011 to June 2013 who survived were reviewed. Infants managed from July 2011 to June 2012 were fed with bovine milk-based fortifiers and formula (BOV). Beginning in July 2012, initial feedings used a human milk-based fortifier to provide EHM feedings. Infants were grouped on the basis of feeding regimen. Primary outcomes were the Bayley-III cognitive scores at 6, 12, and 18 months and growth. Infants ( = 85; 46% received EHM) were born at 26 ± 1.9 weeks ( = 0.92 between groups) weighing 776 ± 139 g ( = 0.67 between groups). Cognitive domain scores were similar at 6 months (BOV: 96 ± 7; EHM: 95 ± 14; = 0.70), 12 months (BOV: 97 ± 10; EHM: 98 ± 9; = 0.86), and 18 months (BOV: 97 ± 16; EHM: 98 ± 14; = 0.71) CA. Growth velocity prior to discharge (BOV: 12.1 ± 5.2 g/kg/day; EHM: 13.1 ± 4.0 g/kg/day; = 0.33) and subsequent growth was similar between groups. EHM feedings appear to support similar growth and neurodevelopment in ELBW infants as compared with feedings containing primarily bovine milk-based products.

Background Premature infants depend on intravenous fat emulsions to supply essential fatty acids and calories. The dose of soybean-based intravenous fat emulsions (S-IFE) has been associated with parenteral nutrition associated liver disease. This study’s purpose was to determine if low dose S-IFE is a safe and effective preventive strategy for cholestasis in preterm neonates. Materials and Methods This is a multicenter randomized controlled trial in infants with a gestation age (GA) ≤ 29 weeks. Subjects < 48 hours of life were randomized to receive a low (1g/kg/day) or control dose (approximately 3g/kg/day) of S-IFE. The primary outcome was cholestasis, defined as a direct bilirubin ≥ 15% of the total bilirubin at 28 days of life (DOL) or full enteral feeds, whichever was later, after 14 days of parenteral nutrition. Secondary outcomes included growth, length of hospital stay, death, and major neonatal morbidities. Results 136 neonates (67 and 69 in the low and control group, respectively) were enrolled. Baseline characteristic were similar for the two groups. When the low group was compared to the control group, there was no difference in the primary outcome (69% vs. 63%, 95% CI (−0.1, 0.22), p=0.45). While the low group received less S-IFE and total calories over time compared to the control group (p<0.001 and p=0.03, respectively) weight, length and head circumference at 28 DOL, discharge, and over time were not different (p>0.2 for all). Conclusion Compared to the control dose, low dose S-IFE was not associated with a reduction in cholestasis or growth.